2023•Nature Reviews Clinical OncologyRequires access

Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma

Edward R. Scheffer Cliff, Talal Hilal, Aaron S. Kesselheim

Open publisher page 12 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ibrutinib, Mantle cell lymphoma, Medicine, Lymphoma, Clinical trial, Bruton's tyrosine kinase, Oncology, Internal medicine

Back to paper search Browse research topics Original source

Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma — Research Paper | ScholarLens